The Insulin Cost Reduction Act
Everywhere this bill has been
4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 20, 2021
Referred to the Subcommittee on Health.
Oct 19, 2021
Referred to the Subcommittee on Health.
Oct 19, 2021
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 19, 2021
Introduced in House
Ask about this bill
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Plain-English summary
The Insulin Cost Reduction Act
This bill prohibits the negotiation of price concessions between insulin manufacturers and prescription drug plans under the Medicare prescription drug benefit unless the price concessions are either provided at the point of sale to beneficiaries or are reflected in cost-sharing requirements.
What's happening now
Referred to the Subcommittee on Health.
Bill text
1 version
- Introduced in House Formatted Text PDF Formatted XML
Committees of jurisdiction
4
Cosponsors
2
Cite this page
U.S. Congress. (2026). H.R. 5623: The Insulin Cost Reduction Act. 117th Congress. Open America. https://openamerica.io/bill/117-HR-5623/
"H.R. 5623: The Insulin Cost Reduction Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-5623/.
H.R. 5623, 117th Cong. (2026), https://openamerica.io/bill/117-HR-5623/.
[H.R. 5623: The Insulin Cost Reduction Act](https://openamerica.io/bill/117-HR-5623/)